# Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

> **NCT01169584** · PHASE1 · COMPLETED · sponsor: **Jennerex Biotherapeutics** · enrollment: 6 (actual)

## Conditions studied

- Neuroblastoma
- Rhabdomyosarcoma
- Lymphoma
- Wilm's Tumor
- Ewing's Sarcoma

## Interventions

- **DRUG:** Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

## Key facts

- **NCT ID:** NCT01169584
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-03
- **Final completion:** 2014-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01169584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01169584, "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01169584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*